Life Sciences Companies: Sell Now or Sell Later?
By Mark Murray Life sciences companies in their early stages are in constant need of capital to continue along their path to meeting clinical milestones. Most are pre-revenue and focused on successful completion of Phase I and II clinical trials. And with strong clinical data, these investment prospects are attractive…Read MoreRead More
Becoming SaaS: How CFOs Need to Manage the Transition from Perpetual to Subscription Models
By Eric Mersch The growing popularity of SaaS applications among end users, enterprise software buyers and investors creates tremendous pressure on traditional software providers to offer subscription versions of their applications. The business case for moving to SaaS is so strong that this business model is projected to dominate all…Read MoreRead More
CFOs Preparing for an IPO: What Are Your Bullseyes?
By Managing Partner, Chris Lowe Every chief financial officer preparing his or her company for an IPO is focused on a key overarching goal – access to public market capital. But at FLG Partners, we know that more experienced CFOs understand the need for much more proactive planning for a…Read MoreRead More
Hotel Tonight: How To Go From a $2.5 million Monthly Cash Burn to Profitability in 2 Quarters
At FLG Partners, we love success stories. And these are always best described in the words of our clients who are in the driver’s seat, taking the risks and making the investments to execute these positive steps forward at their companies. This month, we share a story in First Round…Read MoreRead More